bopaho 125 mg tabletki powlekane
zentiva, k.s. - bosentanum - tabletki powlekane - 125 mg
trocordis 62,5 mg tabletki powlekane
actavis group ptc ehf. - bosentanum monohydricum - tabletki powlekane - 62,5 mg
trocordis 125 mg tabletki powlekane
actavis group ptc ehf. - bosentanum monohydricum - tabletki powlekane - 125 mg
bopaho 62,5 mg tabletki powlekane
zentiva, k.s. - bosentanum - tabletki powlekane - 62,5 mg
perindopril + indapamide krka 8 mg + 2,5 mg tabletki
krka, d.d., novo mesto - tert-butylamini perindoprilum + indapamidum - tabletki - 8 mg + 2,5 mg
perindopril + indapamide krka 4 mg + 1,25 mg tabletki
krka, d.d., novo mesto - tert-butylamini perindoprilum + indapamidum - tabletki - 4 mg + 1,25 mg
rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - Środki przeciwnowotworowe - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
tepmetko
merck europe b.v. - tepotinib hydrochloride monohydrate - rak, niedrobnokomórkowe płuca - Środki przeciwnowotworowe - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
lumykras
amgen europe bv - sotorasib - rak, niedrobnokomórkowe płuca - Środki przeciwnowotworowe - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.
oxbryta
pfizer europe ma eeig - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.